Justifying Psychotropic Drug Prescription Patterns in the UK

InPharma ◽  
1984 ◽  
Vol 437 (1) ◽  
pp. 5-5
Keyword(s):  
Psychotropic Drug ◽  
Drug Prescription ◽  
Prescription Patterns ◽  
The Uk

Psychotropic drug prescription patterns among patients with bipolar I disorder

2000 ◽  
Vol 2 (2) ◽  
pp. 120-130 ◽  
Author(s):  
Joseph Levine ◽  
Kn Roy Chengappa ◽  
Jaspreet S Brar ◽  
Samuel Gershon ◽  
Eric Yablonsky ◽  
...  
Keyword(s):  
Psychotropic Drug ◽  
Drug Prescription ◽  
Bipolar I Disorder ◽  
Prescription Patterns

scholarly journals Consensus and evidence-based medication review to optimize and potentially reduce psychotropic drug prescription in institutionalized dementia patients

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Mireia Massot Mesquida ◽  
Montserrat Tristany Casas ◽  
Alicia Franzi Sisó ◽  
Isabel García Muñoz ◽  
Óscar Hernández Vian ◽  
...  
Keyword(s):  
Psychotropic Drug ◽  
Medication Review ◽  
Drug Prescription ◽  
Evidence Based ◽  
Dementia Patients

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

2018 ◽  
Vol 52 (6) ◽  
pp. 718-723 ◽  
Author(s):  
Shoyo Shibata ◽  
Maiko Matsushita ◽  
Yoshimasa Saito ◽  
Takeshi Suzuki
Keyword(s):  
Cancer Therapy ◽  
Anticancer Drug ◽  
Drug Prescription ◽  
Future Directions ◽  
Prescription Patterns

Drug Prescription Patterns in Schizophrenia Outpatients: Analysis of Data from a German Health Insurance Fund

2009 ◽  
Vol 42 (02) ◽  
pp. 66-71 ◽  
Author(s):  
S. Weinbrenner ◽  
H.-J. Assion ◽  
T. Stargardt ◽  
R. Busse ◽  
G. Juckel ◽  
...  
Keyword(s):  
Health Insurance ◽  
Drug Prescription ◽  
Insurance Fund ◽  
Health Insurance Fund ◽  
Prescription Patterns ◽  
German Health

scholarly journals Polypharmacy and psychotropic drug loading in patients with schizophrenia in Asian countries: Fourth survey of Research on Asian Prescription Patterns on antipsychotics

2018 ◽  
Vol 72 (8) ◽  
pp. 572-579 ◽  
Author(s):  
Shu‐Yu Yang ◽  
Lian‐Yu Chen ◽  
Eunice Najoan ◽  
Roy Abraham Kallivayalil ◽  
Kittisak Viboonma ◽  
...  
Keyword(s):  
Psychotropic Drug ◽  
Drug Loading ◽  
Asian Countries ◽  
Prescription Patterns

scholarly journals How user knowledge of psychotropic drug withdrawal resulted in the development of person-specific tapering medication

2020 ◽  
Vol 10 ◽  
pp. 204512532093245 ◽  
Author(s):  
Peter C. Groot ◽  
Jim van Os
Keyword(s):  
Psychotropic Drug ◽  
Drug Withdrawal ◽  
Full Agreement ◽  
Randomised Controlled ◽  
The Uk ◽  
User Knowledge ◽  
First Time ◽  
Academic Strategy ◽  
Discontinuation Syndrome

Coming off psychotropic drugs can cause physical as well as mental withdrawal, resulting in failed withdrawal attempts and unnecessary long-term drug use. The first reports about withdrawal appeared in the 1950s, but although patients have been complaining about psychotropic withdrawal problems for decades, the first tentative acknowledgement by psychiatry only came in 1997 with the introduction of the ‘antidepressant-discontinuation syndrome’. It was not until 2019 that the UK Royal College of Psychiatrists, for the first time, acknowledged that withdrawal can be severe and persistent. Given the lack of a systematic professional response, over the years, patients who were experiencing withdrawal started to work out practical ways to safely come off medications themselves. This resulted in an experience-based knowledge base about withdrawal which ultimately, in The Netherlands, gave rise to the development of person-specific tapering medication (so-called tapering strips). Tapering medication enables doctors, for the first time, to flexibly prescribe and adapt the medication required for responsible and person-specific tapering, based on shared decision making and in full agreement with recommendations in existing guidelines. Looking back, it is obvious that the simple practical solution of tapering strips could have been introduced much earlier, and that the traditional academic strategy of comparisons from randomised trials is not the logical first step to help individual patients. While randomised controlled trials (RCTs) are the gold standard for evaluating interventions, they are unable to accommodate the heterogeneity of individual responses. Thus, a more individualised approach, building on RCT knowledge, is required. We propose a roadmap for a more productive way forward, in which patients and academic psychiatry work together to improve the recognition and person-specific management of psychotropic drug withdrawal.

scholarly journals Evaluation of Psychotropic Drug Use in Adolescents Accessing a General Emergency Medical Department for Mental Disorders

Adolescents ◽  
2020 ◽  
Vol 1 (1) ◽  
pp. 1-9
Author(s):  
Martina Buttera ◽  
Antonio Clavenna ◽  
Lucia Tansini ◽  
Erica Maselli ◽  
Alessandro Albizzati ◽  
...  
Keyword(s):  
Drug Use ◽  
Mental Disorders ◽  
Mental Disorder ◽  
Psychotropic Drug ◽  
Pediatric Population ◽  
Drug Prescription ◽  
University Hospital ◽  
Medical Department ◽  
Off Label ◽  
Psychotropic Drug Use

Background: Given the paucity of data concerning the care of adolescents attending an emergency department (ED) for mental disorders, we performed an observational study with the aim to describe psychotropic drug use in an Italian ED. Methods: A retrospective chart review of adolescents (13–17 years) visited in the ED of the San Paolo University Hospital in Milan for mental disorders between January and June 2018 was conducted. Information concerning age, gender, type of disorder, psychotropic drug use in the ED and outcome of the visit were analyzed, using an anonymous patient code. Results: A total of 1298 adolescents, 13–17 years old, were visited in the ED, 56 (4%) of whom had a diagnosis of mental disorder (34 females and 22 males). The most common disorder was anxiety (21 patients), followed by predominant psychomotor disorder (13 patients). In all, 30 adolescents received a psychotropic drug. Benzodiazepines were the most commonly used drugs (73% of the subjects), and delorazepam was administered/prescribed to 17 adolescents, despite the fact that evidence on its safety, efficacy, and its off-label use in the pediatric population is lacking. Conclusions: One out of two adolescents attending the ED for an acute episode of mental disorder received a psychotropic drug prescription, mainly in an off-label manner. More evidence is needed to guide the pharmacological management of acute episodes of mental disorders.

Sign in / Sign up

Export Citation Format

Share Document